Solidarité de l’UE avec l’Ukraine
Prozorro+: plateforme ukrainienne des marchés publics
Unrevised Machine Translation
Belgium-Brussels: Research and experimental development services
Section I: Contracting authority
This pre-commercial purchase
(PCP) is carried out by SCIENSANO, which has been designated as lead buyer. The applicable national law on contracts
applicable is Belgian law.
Section II: Object
Pre-commercial purchases for the acquisition of R & D services for the development of a solution for liquid solid tumour biopsies based on solid NGS. tumours technology, based on NGS technology
Compiling the musational profile of tumours requires complex, invasive and costly procedures, but it is
but quickly becomes essential for effective and adequate management of cancer patients, especially when the disease has already reached a metastatic stage.
disease has already reached metastatic stage, where identification of tumour biomarkers is relevant to identify the best
the most targeted therapy. However, access to tumour tissues remains a limiting factor for the assessment of biomarkers, and
more and more evidence suggests that they may even be inadequate to capture clonal heterogeneity that often leads to resistance.
The assessment of circulating biomarkers is rapidly gaining ground as a non-invasive alternative offering the additional opportunity to monitor the evolution of the disease in series.
ability to track the course of the disease in series and obtain a more complete picture of the genetic heterogeneity of the tumour.
genetic heterogeneity of the tumour. However, the current trajectory for the development of large-scale cfDNA tests is highly dependent on expensive, high-throughput centralised sequencing.
expensive, high-speed and centralised, and seems poorly adapted to common practice in Europe.
PCP oncNGS aims to develop an integrated solution for predictive, prognostic and diagnostic analysis of liquid biopsies.
solid tumours (including appropriate haematological indications) based on NGS technology.
This PCP responds to the unmet global need for oncology, which consists of profiling multiple tumours at molecular level in the broadest possible way.
to the widest possible extent, promoting an economically sustainable and decentralised model that allows secure and transparent access to sensitive data.
sensitive data. All partners in this consortium agree that they face a common challenge: provide "the best NGS tests, for
all solid and lymphoid tumours, always”. They agree that a jointly identified public contract meets a need shared by all
the buyers of the group of buyers of the project which is the subject of this proposal for a public procurement contract ‘oncNGS’.
More information on the objective of the PCP oncNGS and the PCP Challenge can be found in the various annexes.
R &Dwill be carried out mainly in Europe.
The tests should take place in Brussels (Be), Paris, Lyon (Fr), Berlin, Munich (GER), Barcelona (Sp), Milan, Rome (It).
Routine profiling of tumours requires complex, invasive and costly procedures, but quickly becomes essential for
effective and adequate treatment of cancer patients, especially when the disease has already reached the metastatic stage.
where the identification of tumour biomarkers is relevant to identify the best targeted therapy. However, access
However, access to tumour tissues remains a limiting factor for the assessment of biomarkers, and growing evidence suggests that it can even be
insufficient to capture the clonal heterogeneity that is often the cause of resistance. The assessment of circulating biomarkers is rapidly gaining ground as a non-invasive tool.
The assessment of circulating biomarkers is rapidly gaining ground as a non-invasive alternative offering an additional opportunity to track the evolution of the disease in series.
the possibility of obtaining a more complete picture of the genetic heterogeneity of the tumour. However, the current development path
However, the current development trajectory for large-scale cfDNA tests is highly dependent on cost-intensive centralised high speed sequencing and seems ill-suited to common practice in Europe.
common practice in Europe.
This project was funded by the EU’s Horizon 2020 research and innovation programme.
under Grant Agreement No 874467
See the attached document Invitation to Tender and the other tender documents.
Section III: Legal, economic, financial and technical information
Class: N/A, Category: N/A
Section IV: Procedure
Section VI: Complementary information